Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Toyama Chemical gets Japanese rights to Cempra's solithromycin

Executive Summary

Antibiotics developer Cempra Inc. has licensed Toyama Chemical Co. Ltd. (majority owned by Fujifilm Holdings Corp.) exclusive rights to develop and commercialize in Japan its solithromycin (CEM101)--or any product that incorporates the active pharmaceutical ingredient--for all indications except ophthalmic.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies